Jane Tu

HistoRx is developing novel diagnostic solutions to enable new approaches to individualized patient care. The company accomplishes this through analysis of protein biomarkers in tissue using its proprietary AQUA(R) technology. These reproducible and quantifiable tissue-based immunoassays correlate protein expression with disease outcome. HistoRx signed its first diagnostic licensing agreement with Genoptix in February 2010, the premier U.S. oncology clinical laboratory, for their use in offering several diagnostic assays. Three breast cancer assays were launched in 2010, making AQUA technology available to the general public for the first time. AQUA software for fluorescent image analysis is now available on Aperio's new ScanScope FL, a multi-slide fluorescence scanning system designed to meet the growing demand for multiplexing with fluorescent biomarkers and quantitative analysis. HistoRx recently signed a value-added reseller agreement with Caliper Life Sciences as well, and the two companies are working together to integrate AQUA software with the Nuance(TM) and Vectra(TM) hardware offered by Caliper.